Compare Icl Group Ltd (ICL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Sana Biotechnology Inc — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Icl Group Ltd is far larger — about 7.7× Sana Biotechnology Inc's market cap, and Icl Group Ltd pays a 4.11% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Sana Biotechnology Inc for 23 Days on average.
| ICL | SANA | |
|---|---|---|
Market Cap | $6.47B | $836.71M |
Volume | 1,387,140 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $5.92 |
52-Week Low | $4.80 | $2.68 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $9.11B | $749.96M |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.02, down 1.18% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, but revenue and net income have declined from 2022 peaks. Valuation appears reasonable with P/E of 20.83 and P/S of 0.84, while analyst consensus is entirely Hold with a $6.08 price target. Recent news highlights dividend strength and cost-transformation initiatives.
The outlook is mixed: earnings beats and dividend yield offer support, but declining profitability and industry headwinds pose challenges. Upside exists if cost cuts and price stabilization materialize, though margin pressure and competitive threats remain key risks for investors.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
